Department of Pathology, State University of New York at Stony Brook



Go to:

TOC

Prev

Next

Classifying Non-Hodgkin's Lymphomas

CLASSIFYING non-Hodgkin's lymphomas makes sense for several reasons:

  1. The categories appear to correspond to biological entities that behave distinctly. Thus the pathologist gives the clinician important guidance for treating the lymphoma and assessing its prognosis.
  2. A knowledge of the features of each category helps the pathologist to recognize a lymphoma. Since lymphomas can assume a bewildering variety of appearances, it's helpful to know what the coherent patterns are.
  3. By observing how the lymphomas group themselves, one can discover important biological principles that underlie their appearance and behavior.
H&E stained tissue
       Pathologists have traditionally depended heavily on the morphologic appearances of lymphomas to categorize them. Twenty years ago, morphology was the only tool available. Suspicious lymphoid tissue was (and still is) fixed in formalin or a mercury-containing fixative, embedded in paraffin, sliced very thinly (5 microns or less), placed on a glass slide, and stained with the all-purpose tissue stain, hematoxylin and eosin. The earliest attempts to categorize lymphomas relied solely on this method.
       Starting in the 1970's other techniques have been developed to study the nature of both benign and malignant lymphoid cells.
  • ImmunophenotypingMembrane antigens: Different types of lymphoid cells express different molecules on their surface cell membrane. Clever scientists enhance their careers by making antibodies that will adhere specifically to these molecules, in this context called antigens. If the antibodies are altered in special ways so their presence can be detected (for example, they may be rendered fluorescent), this technique can be used to assess what kinds of antigens decorate the cell membrane. These antibodies are eventually given so-called "cluster designation" or "CD" numbers. Immunophenotyping has become important in evaluating 1) the malignancy of a lymphoid proliferation and 2) the lymphoma category to which it belongs. Three methods of immunophenotyping that yield the similar information are:
      1) immunohistochemistry
      2) immunofluorescence
      3) flow cytometry.
  • Cytogenetics: Like all cells, malignant lymphoid cells can be made to proliferate in vitro, and their metaphase chromosomes can be examined for characteristic translocations. It is encouraging to the morphologically oriented hematopathologist that his or her careful microscopic observations very frequently correspond to genetic distinctions uncovered by "scientific" techniques. As Oscar Wilde said, only very superficial people are uninterested in surface appearances.
  • Molecular analysis: This technique is usually geared toward finding clonal (neoplastic) rearrangements of the immunoglobulin gene in B-cell malignancies or of the T-cell receptor gene in T-cell malignancies. These rearrangements are too subtle to be detected by conventional cytogenetics.
       Most classifications are based on the assumption that lymphoma cells are the malignant counterparts of benign lymph node cells. The various lymphomas are often named after the benign cell from which they are assumed to derive.

Rappaport Classification
The oldest classification that still crops up is the Rappaport classification, which was developed before lymphoid cells were divided into B-cells and T-cells. Occasionally the following terms may be heard:

  • Well-differentiated lymphocytic lymphoma = small lymphocytic lymphoma.
  • Poorly differentiated lymphocytic lymphoma = follicular center cell lymphoma with a large component of small-cleaved cells.
  • Histiocytic lymphoma = large cell lymphoma
Kiel and Lukes & Collins Classification
A gala year for classifications, 1974 saw the introduction of 2 new ones. (In fact the diversity and complexity of classifications had reached the point that one British physician was moved to publish a parody in The Lancet.) The Kiel Classification is popular in Europe. The Lukes and Collins Classification, which was the first to separate B-cell and T-cell lymphomas using immunologic techniques, has been popular in the United States. Some of the terminology from both classifications has made its way into the lingua franca of hematopathology.

Working Formulation
By the early nineteen-eighties, so many classifications and systems had proliferated that a large study was initiated to separate the sheep from the goats (i.e., tell which systems were valid). Investigators at the National Cancer Institute looked at 1175 cases of non-Hodgkin's lymphoma and concluded that each of the classifications had clinical value but none was clearly superior. True hematopathologists, they therefore invented yet another classification, a meta-classification called the Working Formulation. It is important (or at least interesting) to remember that this grouping:

  • was originally intended to translate among the previous classifications, not to replace them.
  • was based solely on the morphology of H&E stained sections.
  • groups the lymphomas into morphologic categories that may encompass several individual diseases.
      Despite these drawbacks, the Working Formulation probably provides the most common convenient terminology for discussing lymphomas. The Formulation's categories do have clinical validity (therapeutic and prognostic), are based on relatively simple morphologic features, and for this reason offer diagnostic criteria that are reproducible among pathologists.
       The criteria are both architectural (low magnification) and cytological (high magnification):
  1. Architectural
    • diffuse proliferation
    • follicular proliferation
  2. Cytological
    • Nuclear outline
      • cleaved (indented)
      • non-cleaved
    • Cell size
      • small
      • large
      • mixed small and large
      Note that there is no consideration of B or T-lineage. Using data from the study of the original 1175 cases, the Working Formulation entities are divided into low, intermediate, and high grade lesions. This is the information that is most important to the treating clinician.
 

Working Formulation

Low Grade

Intermediate Grade

High Grade

Small lymphocytic

Follicular large cell

Large cell immunoblastic

Follicular small-cleaved cell

Diffuse small cleaved cell

Lymphoblastic

Follicular mixed small-cleaved and large cell

Diffuse mixed small and large cell

Small non-cleaved cell (Burkitt's and non-Burkitt's type)

 

Diffuse large cell

 

Revised European and American Lymphoma Classification
As the years have rolled by, many additional lymphomas have been distinguished, sometimes with the help of immunologic, cytogenetic and molecular techniques. Recently an informal group of hematopathologists, the International Lymphoma Study Group, proposed a consensus list of lymphomas, the Revised European-American Lymphoma classification. This list sets forth the diagnostic features of lymphomas that the group members consider currently widely recognized and diagnosable by contemporary techniques.
       This classification is satisfying to many hematopathologists because it is up-to-date and details the lymphomas that they have been trained to recognize. It has been criticized, however, particularly by non-specialist clinicians who think that 1) it distinguishes more entities than they know what to do with clinically and 2) it fails to supply grading information as a guide for therapy. Whether or not one accepts it as a satisfying classification, it is a useful list of currently more-or-less well-characterized lymphomas.

B-Cell Neoplasms

I. Precursor B cell neoplasm:
    1. B-lymphoblastic leukemia/lymphoma

II. Peripheral B cell neoplasms

  1. B cell chronic lymphocytic leukemia / small lymphocytic lymphoma
  2. Lymphoplasmacytoid lymphoma/immunocytoma
  3. Mantle cell lymphoma
  4. Follicle center lymphoma, follicular,
    Provisional cytological grades: small cell, mixed small and large cell, large cell
    Provisional subtype: diffuse, predominantly small cell type
  5. Marginal zone B cell lymphoma
    • Extranodal (MALT type ± monocytoid B cells)
    • Nodal (± monocytoid B cells)
    • Splenic (± villous lymphocytes)
  6. Hairy cell leukemia
  7. Plasmacytoma/myeloma
  8. Diffuse large cell B-cell lymphoma
    • Subtype: primary mediastinal (thymic) B cell lymphoma
  9. Burkitt's lymphoma
  10. Provisional category: high grade B-cell lymphoma, Burkitt's-like
T-Cell and Putative Natural Killer Cell Neoplasms

I. Precursor T cell neoplasm:
    1. T precursor lymphoblastic lymphoma/leukemia

II. Peripheral T cell and NK-cell neoplasms

  1. T cell chronic lymphocytic leukemia / prolymphocytic leukemia
  2. Large granular lymphoproliferative (LGL) disorder
    • T-cell type
    • NK-cell type
  3. Mycosis fungoides/Sézary's syndrome
  4. Peripheral T cell lymphoma (small cell, mixed small and large cell, large cell)
    Provisional subtype: lymphoepithelioid cell lymphoma
  5. Angioimmunoblastic T cell lymphoma (AILD)
  6. Angiocentric lymphoma
  7. Intestinal T cell lymphoma (± enteropathy associated)
  8. Adult T cell lymphoma/leukemia (ATL/L)
  9. Anaplastic large cell lymphoma (ALCL), CD30+, T and null-cell types
Hodgkin's Disease

  1. Lymphocyte predominance
  2. Nodular sclerosis
  3. Mixed cellularity
  4. Lymphocyte depletion
  5. Provisional category: Lymphocyte-rich classic HD
  6. Provisional category: Anaplastic large cell lymphoma, Hodgkin's like
Unclassifiable

  1. B cell lymphoma, unclassifiable (low grade/high grade)
  2. T cell lymphoma, unclassifiable (low grade/high grade)
  3. Malignant lymphoma, unclassifiable

Table of Contents | Next section | Previous section